|

Re-optimization Based Online Adaptive Radiotherapy of Anal Cancer

RECRUITINGSponsored by Herlev Hospital
Actively Recruiting
SponsorHerlev Hospital
Started2022-01-01
Est. completion2026-01-01
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT05438836

Summary

A single-arm, prospective, Phase II, single-center clinical trial that will investigate if daily online adaptive radiotherapy for anal cancer will significantly reduce early treatment-related GI toxicity compared with the historically reported rate for non-adaptive intensity modulated radiation therapy (IMRT).

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Biopsy-verified anal cancer
* Eligible for curative intended radiotherapy
* Written and oral consent

Exclusion Criteria:

* Other malignant disease within the past 5 years (excluding basal cell carcinoma)

Conditions4

Anal CancerAnal CarcinomaAnal Squamous Cell CarcinomaCancer

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.